diabetestalk.net

Medtronic Diabetes Site

Medtronic Launches Engagement Program For Diabetes Patients

Medtronic Launches Engagement Program For Diabetes Patients

Medtronic launches engagement program for diabetes patients Medtronic (NYSE: MDT ) said today that it launched its Inner Circle patient engagement program in the U.S. The medtech titans program,which is designed for people living with diabetes, uses gamification to motivate and encourage its users to practice behaviors that help them control their blood sugar levels. The Inner Circle program also gives users a place to form a community where they can challenge each other and track their progress. Medtronic reported that the company was inspired to create the Inner Circle program when it learned that 88% of people using its MiniMed 670G automated insulin delivery system were interested in a program that could help boost their diabetes management. Users will be invited to enroll in the program once they are on Medtronics 670G system or the Guardian Connect smart continuous glucose monitoring system, according to Medtronic. Diabetes is unrelenting, and we are committed to innovating in new ways beyond technology to provide inspiration, motivation and education to help people with diabetes on their journey to better health, Louis Dias, chief patient officer for Medtronics diabetes business, said in prepared remarks. As the leader in patient-centric care, we are working to enhance patients lives through the Medtronic Inner Circle program, which demonstrates our ongoing commitment to providing new and innovative offerings to people living with diabetes. Our new therapies such as the MiniMed 670G system can help increase Time in Range and reduce hypoglycemic events, Dr. Fran Kaufman, chief medical officer for Medtronics diabetes group, added. This novel and innovative program gives patients tools and challenges them to improve their diabetes management and spend more Time in Continue reading >>

Infusion Set Lot Check | Medtronic Diabetes

Infusion Set Lot Check | Medtronic Diabetes

Algeria, Cte d'Ivoire, Egypt, Iran, Iraq, Jordan, Kenya, Kuwait, Lebanon, Libya, Mauritius, Morocco, Namibia, Oman, Pakistan, Qatar, Sudan, Tunisia, Tanzania, United Arab Emirates, Yemen The content and all information provided on this website is for your informational use only and is not intended to be a substitute for professional medical advice, diagnosis or treatment in any manner. The patient stories provided are experiences specific to a particular patient. Responses to a treatment may vary from patient to patient. Always talk with your physician about diagnosis and treatment information and ensure that you understand and carefully follow that information. 2018 Medtronic International Trading Sarl. All Rights Reserved. No part of this website may be reproduced or utilized in any form or by any means without permission from Medtronic International Trading Sarl. MiniMed, Bolus Wizard, SMARTGUARD, Guardian, Enlite and CareLink are trademarks of Medtronic, Inc. and its subsidiaries. CONTOUR is a trademark of Ascensia Diabetes Care. Continue reading >>

Medtronic

Medtronic

Medtronic Public Limited Company is a medical device company. Its headquarters are in Dublin, Ireland.[1][3][4][5] Its operational headquarters are in Fridley, Minnesota.[1][6] Medtronic is among the world's largest medical equipment development companies.[7] In 2015, at the time of its acquisition of Covidien, its market capitalisation was about $100 billion.[8] Medtronic operates in more than 140 countries.[1] It employs over 85,000 people and has more than 53,000 patents.[9] History[edit] Early history[edit] Medtronic Operational Headquarters in Fridley, Minnesota, a suburb of Minneapolis. Medtronic was founded in 1949 in northeastern Minneapolis by Earl Bakken and his brother-in-law, Palmer Hermundslie, as a medical equipment repair shop.[10] Through his repair business, Bakken came to know C. Walton Lillehei, a doctor of heart surgery at the University of Minnesota Medical School. The deficiencies of the pacemakers of the day were made painfully obvious following a power outage over Halloween in 1957, which affected large sections of Minnesota and western Wisconsin.[11] A pacemaker-dependent paediatric patient of Lillehei died because of the blackout. The next day, Lillehei spoke with Bakken about developing some form of battery-powered pacemaker. Bakken modified a design for a transistorised metronome and created the first battery-powered external artificial pacemaker. Medtronic's old headquarters in St. Anthony, Minnesota The company expanded through the 1950s, mostly selling equipment built by other companies but also developing some custom-made devices. Bakken built a small pacemaker that could be strapped to the body and powered by batteries. Work in the new field later produced an implantable pacemaker in 1960. The company built headquarters in the Minneapoli Continue reading >>

Newsflash: New Medtronic Device Combines Cgm Sensor & Insulin Infusion Site

Newsflash: New Medtronic Device Combines Cgm Sensor & Insulin Infusion Site

Medtronic is leading the charge on new diabetes devices again, with a first-of-its-kind combo device launched in Europe that brings a continuous glucose monitoring (CGM) sensor and insulin infusion set together into a single device with combined insertion capability! The company announced its launch of the Minimed Duo on Tuesday, after getting CE Mark approval for European sale early this week. The new Duo uses the Minimed Veo system (which is the 2009-approved European version of the new Minimed 530G system that was approved in the U.S. last fall) and the accompanying Enlite sensor. The magic here is that the Duo merges the insertion needs for both insulin infusion and CGM monitoring into just one spot on the body -- instead of two different sites on your body as has always been required. Note that this is not the full dream of a single cannula -- you'd still have two puncture spots on the skin where the steel catheter and glucose sensor go in -- but you'd only have to push one button on a single, combined inserter to place both your insulin pump and CGM automatically, plus the needles retract so you don't have to see them. The downside? Since the CGM sensor and infusion set are now connected, you are forced to change them both out at the same time every three days. This of course means that the Medtronic CGM would go from 6-day wear to 3-day wear, which seems like a "a step back" from the current Veo system and Enlite sensor -- although Medtronic disagrees that it's a disadvantage. It's a balancing of factors, the company tells us, and customer feedback for years has been clamoring for a single-site device. So Medtronic sees this as a trade-off that will appeal to many people. A smaller footprint on the body of course means less tape and less skin "real estate" to use Continue reading >>

Insuliinipumppu Medtronic Diabetes, Suomi

Insuliinipumppu Medtronic Diabetes, Suomi

Tmn verkkosivuston sislt ja kaikki sen sisltmt tiedot esitetn vain tiedotustarkoituksessa, eik niill ole tarkoitus milln tavoin korvata lketieteen ammattilaisten antamia neuvoja, diagnooseja tai hoitoa. Esitetyt potilaskertomukset ovat yksittisiin tapauksiin liittyvi kokemuksia. Hoitovasteet voivat vaihdella potilaan mukaan. Keskustele aina lkrisi kanssa diagnoosista ja hoitoa koskevista tiedoista ja varmista, ett ymmrrt nm tiedot ja noudatat ohjeita huolellisesti. Medtronic ei vastaa vahingoista tai vaurioista, jotka aiheutuvat tai joiden vitetn aiheutuvan suoraan tai vlillisesti tmn verkkosivuston sisltmist tiedoista. Luettelo kyttaiheista, vasta-aiheista, varotoimista, varoituksista ja mahdollisista haittavaikutuksista on kunkin tuotteen kyttohjeissa. 2016 Medtronic International Trading Sarl. Kaikki oikeudet pidtetn. Mitn tmn sivuston osaa ei saa jljent tai hydynt missn muodossa eik milln tavoin ilman Medtronic International Trading Sarl -yhtin lupaa. MiniMed, Bolus Wizard, SMARTGUARD, Guardian, Enlite ja CareLink ovat Medtronic, Inc.:n ja sen tytryhtiiden tavaramerkkej. CONTOUR on Ascensia Diabetes Care Finland Oy:n tavaramerkki. Continue reading >>

Medtronic Diabetes Laying Off More Than 400 At Northridge Site

Medtronic Diabetes Laying Off More Than 400 At Northridge Site

edtronic Diabetes is laying off more than 400 workers at its Northridge facility as the company consolidates and shifts its customer service operation to Texas, officials said Wednesday. A total of 464 positions will be eliminated by October 30, including about 300 customer service jobs being transferred to San Antonio, spokeswoman Amanda Sheldon said. Those call-center employees were offered the chance to relocate. About 1,800 employees will remain at the Devonshire Street campus, which is the headquarters for Medtronic Diabetes and where the company conducts research and manufactures insulin pumps and glucose monitoring systems. To my knowledge we are committed to the division we have here as of right now, Sheldon said. We are restructuring the diabetes business to increase operating efficiencies. Medtronic Inc., an international company based in Minneapolis, said in February it would eliminate about 2,100 jobs in response to market conditions. And in May 2009, it announced that San Antonio would be home to its new Diabetes Therapy Management and Education Center. At the time the company said it would staff the center with 1,400 workers over a five-year period. The company addressed its Northridge operation in that press release. Medtronic continues to invest and grow its headquarters in Northridge and commitment to California employees remains strong, it said. An analysis by the San Antonio Economic Development Foundation said the Medtronic facility will generate more than $750 million annually in economic benefits. Foundation President Mario Hernandez said his city attracted Medtronic through its business-friendly, low-cost reputation. They are going to save 30 to 40 percent on all cost factors versus Los Angeles, he said. And (workers) can live very comfortably ve Continue reading >>

Medtronic Announces Voluntary Recall Of Diabetes Infusion Sets

Medtronic Announces Voluntary Recall Of Diabetes Infusion Sets

Announcement Medtronic plc (NYSE:MDT) announced today that it has started to inform patients worldwide of a voluntary recall of specific lots of infusion sets used with all models of Medtronic insulin pumps. The recall is related to a certain discontinued component in these infusion sets and does not include insulin pumps or glucose sensors. The company determined, through recent field reports from patients and root cause analysis, that a component, the vent membrane, in the recalled infusion sets may be susceptible to being blocked by fluid during the process of priming/fill-tubing. This situation can lead to potential over-delivery of insulin shortly after an infusion set change, which may cause hypoglycemia. Currently manufactured infusion sets, available to patients since April 2017, include a design update of this component which the company believes reduces the risk of insulin over-delivery after an infusion set change. The company will work with patients to ensure recalled infusion sets with the discontinued component are returned and replaced with new infusion sets containing the updated component at no cost. Medtronic has contacted the U.S. Food and Drug Administration (FDA), along with other regulatory bodies around the world, to share information related to this issue. Medtronic will continue working directly with government and regulatory authorities on this global voluntary recall. "Our priority is to work with our patients to mitigate risk to patient safety. While we have shipped a significant number of the new and enhanced sets since April, we are committed to replacing recalled infusion sets for all patients," said Francine Kaufman, M.D., chief medical officer of the Diabetes Group at Medtronic. "Our Medtronic Diabetes team will work as quickly as possib Continue reading >>

Medtronic Recalls Diabetes Infusion Sets For Overdose Risk

Medtronic Recalls Diabetes Infusion Sets For Overdose Risk

1 in 2 million sets susceptible to excess insulin delivery Company to replace sets at no cost; no financial details given Medtronic Plc is recalling a disposable device used with the company’s insulin pumps, after discovering that the part can trigger an excessive dose of the drug and put patients at risk of hypoglycemia. About one in every two million infusion sets manufactured before April may be associated with the complication, which occurs when a membrane that’s used to release pressure from inside the pump gets wet and blocks the vents, said Francine Kaufman, chief medical officer of Medtronic’s diabetes group. The risk of an excessive insulin dose is greatest right after the patient changes the infusion set, which is done every three days, she said. “Shortly after that change, the patient could experience insulin over-delivery,” she said in a telephone interview. There haven’t been any deaths associated with the flaw, Kaufman said. Most patients who had a problem were aware that their blood sugar had gone too low and were able to treat the condition. Others called an ambulance, went to the hospital or saw their doctors, she said. For patients with an infusion set that is in and working, nothing needs to be done, said Annette Bruls, president of Medtronic’s diabetes service and solutions business. Medtronic says it has fixed the problem and patients can use the devices that were made from April on. Medtronic, based in Dublin and run from Minneapolis, said the majority of the cost from the recall is expected to be incurred in the second quarter of the company’s fiscal year and will depend on the amount of unused sets that patients return. It isn’t expected to reduce earnings in the quarter or the full year, or impact revenue growth in the diabetes Continue reading >>

Medtronic Address

Medtronic Address

medtronic address Please enter your User ID and password to enter the Medtronic CareLink Clinician Website. They can be contacted via phone at (216) 642-1977 for pricing, hours and directions. Information about the lead(s) and battery function is continuously updated. Medtronic, Inc. Medtronic Headquarters Info. Contact us to learn more about the RDN procedure. Medtronic's superDimension Navigation System aids the diagnosis of lung disease leading to earlier, personalized treatment. medtronic. Environmental profile of Medtronic Physiological Research Lab Prl. See who you know at Medtronic, leverage your professional network, and get hired. 787-844-4526. The six major businesses focus their efforts around a condition or therapy type: Cardiac Rhythm Disease Management, Spinal and Biologics, CardioVascular, Neuromodulation, Diabetes, and Surgical Technologies. Marieke Eissmann from Essen, Germany is a concise overview of using echocardiography when evaluating patients supported with HVAD therapy. Medtronic: 1-800-633-8766 (toll-free within the United States) or 763-514-4000 (worldwide). Medtronic Headquarters is a 4-story low-rise building in Fridley, Minnesota, U. Highlight your Business in our Directory - Contact Us Shop LIFEPAK CR Plus, EXPRESS and LIFEPAK 1000 AEDs from Physio-Control (formerly Medtronic). See reviews, photos, directions, phone numbers and more for Medtronic locations in New Haven, CT. com. Medical device giant Medtronic said Tuesday it is reviving plans to divest its Redmond-based Physio-Control unit, an early pioneer of the Find company research, competitor information, contact details & financial data for Medtronic Sofamor Danek Usa, Inc. Check this page often, or follow Medtronic (hit the follow button up top) to keep updated on their latest disco Continue reading >>

Mdt Stock Price - Medtronic Plc Stock Quote (u.s.: Nyse) - Marketwatch

Mdt Stock Price - Medtronic Plc Stock Quote (u.s.: Nyse) - Marketwatch

Medtronic PLC MDT reported its third-quarter earnings Tuesday. Here's what you need to know: EARNINGS: The medical-equipment company reported a net loss of $1.4 billion, or $1.03 a share, due to impacts from the U.S. tax law overhaul. On an adjusted basis, the company earned $1.17 a share, which is what analysts polled by Thomson Reuters had expected. Health care stocks turn upward as market rebounds Health care stocks moved upward in Tuesday morning trade as the market began to reverse its previous weakness, though some pharmaceutical stocks continued to drag. The Health Care Select Sector SPDR rose 0.8%, the SPDR S&P Pharmaceuticals ETF rose 1.6% and the SPDR S&P Biotech ETF rose 1.3%, compared with a 0.5% rise in the S&P 500 and a 0.4% drop in the Dow Jones Industrial Average . Shares of Mylan NV rose 2.6%, Shire PLC rose 2.1%, Johnson & Johnson rose 1.5%, Eli Lilly & Co. rose 1.7%, Danaher Corp. rose 1.4% and UnitedHealth Group rose 0.8%. Some biopharmaceutical stocks continued their weakness on Tuesday, however, including Sanofi , which declined 0.9%, Bristol-Myers Squibb , which declined 1.4%, Medtronic , which declined 0.9%, and Neurocrine Biosciences , which declined 1.7%. Despite having dropped 4.4% on Monday, matching widespread market weakness, the health Care Select Sector SPDR has gained 1.5% year-to-date, compared with a 0.2% decline in the S&P 500 and a 1.5% decline in the Dow Jones Industrial Average. Among the companies with shares expected to trade actively in Tuesday's session are WalMart, NXP Semiconductors, Rite Aid, Facebook and Home Depot. CEO Omar Ishrak says value-based contracts are the future of care. The network is streaming 1,800 hours of Winter Olympics coverage. Its still not quite ready for prime time, however. The new law has something Continue reading >>

Diabetes Your Health

Diabetes Your Health

Diabetes is a disease in which the body does not produce or use insulin properly. Insulin is a hormone that is needed to convert sugar, starches and other food into energy needed for daily life. The exact cause of diabetes is unknown, although both genetic and environmental factors, as well as lifestyle issues (for example, obesity and lack of exercise) appear to play roles. There are two major types of diabetes, known as Type 1 and Type 2. Type 1 diabetes is often diagnosed in children and teenagers, and for this reason was once called juvenile onset diabetes. However, people of all ages can be diagnosed with Type 1 diabetes. The cause is unknown, though there seems to be a strong family link that can be triggered by environmental factors such as viruses. Type 1 diabetes does not appear to be related to lifestyle or obesity. Type 1 diabetes occurs most often in children and young adults and accounts for 10-15% of diabetes cases in Australia.1 Type 2 diabetes affects over 1 million people in Australia, making it the most common form of diabetes.2While it was once called adult onset diabetes, children and teenagers can develop Type 2 diabetes as well. Continue reading >>

670g And Me: Insights And Incites On Medtronic’s Latest System

670g And Me: Insights And Incites On Medtronic’s Latest System

What’s the purpose of a diabetes management device? Is it to lower A1c? Prevent hypoglycemia? Spend more time in-range? Some combination of all three? Or perhaps we have to look beyond blood sugar control. After all, quality of life has to count for something. Does it make living with diabetes safer and easier? My Detailed Review of The MiniMed 670G from Medtronic The MiniMed 670G from Medtronic is an insulin pump coupled with a glucose sensor. It uses a computer program (called an “algorithm”) to automate certain aspects of insulin delivery. I decided to try 670G partially out of professional interest (everybody and their great aunt has been asking for my opinion on the system), and partially out of personal interest, as my blood glucose control hasn’t been the greatest the past couple of years. Let me start out by saying this: Since I started using 670G, my overall blood glucose control is better. I have to keep reminding myself of this non-consequential fact, because every day I find things about this system that I don’t particularly like. In my opinion, the pump itself leaves a lot to be desired. There are so many features and so many menus and so many safety/confirmation steps that my button thumb is starting to form a blister. The color screen is nice, but not large enough to display everything it needs to display. And the freakin’ clip is upside down. The reservoir connector pokes me in the gut every time I bend over, and I have to unclip it to see the screen and programming menus in the proper orientation. The “hybrid closed loop” part of the system (what I prefer to call the “semi-automatic feature”) is what makes 670G special. It functions by making adjustments to the BASAL insulin based on data received from the linked glucose sensor. Sinc Continue reading >>

Disaster Relief - Jdrf

Disaster Relief - Jdrf

If you are facing a life-threatening emergency, please call 911. For those of you who need assistance, there are resources to help. Diabetes Disaster Response Coalition Facebook In addition, you can also mark yourself Safe on Facebook. If an emergency has forced you to evacuate your home, the Red Cross may be able to help. After a disaster, the Red Cross encourages individuals to list themselves as Safe and Well for family members to easily be able to locate those impacted by natural disasters. Monday through Friday, 9:00 a.m. to 7:00 p.m. ET For healthcare providers only: 1-314-INSULIN (call or text) Diabetes Disaster Relief Coalition (DDRC) JDRF and other leading diabetes organizations have joined forces through the Diabetes Disaster Response Coalition (DDRC) to ensure that people with diabetes have the support, insulin and supplies they need in advance of a major storm. The DDRC is urging all people with diabetes and their loved ones in vulnerable locations to prepare by putting together a diabetes kit and plan to stay safe. Download the Patient Prepardness Plan and check list to assist in completing your kit. Insulin For Life USA provides insulin and disease management supplies free of charge to those with diabetes who otherwise would go without these life-saving provisions in underdeveloped countries and disaster affected areas. IFL-USA is accepting donations of unexpired insulin (vials, pens, and cartridges), test strips, meters, lancing devices and, Glucagon kits. Continue reading >>

Medtronic's Diabetes Business Posts Highest Quarterly Sales Growth In More Than 10 Years - Minneapolis / St. Paul Business Journal

Medtronic's Diabetes Business Posts Highest Quarterly Sales Growth In More Than 10 Years - Minneapolis / St. Paul Business Journal

Senior Reporter, Minneapolis / St. Paul Business Journal Medtronic reported earnings that beat analysts estimates Tuesday, as company officials said the med-tech giants diabetes unit performed better than it has in more than a decade. The company recorded adjusted first-quarter revenue of $7.4 billion, down slightly compared to the year-ago period but above analysts' projected $7.24 billion. Adjusted first-quarter net income rose to $1.6 billion, or $1.17 per share. That's up about 4 percent from the first quarter of Medtronic's 2018 fiscal year and beat Wall Street estimates of a $1.11 per share. Adjustments accounted for in those numbers include last years sale of several business lines to Cardinal Health Inc. in a $6.1 billion deal . Overall, sales rose across Medtronics businesses, with revenue in its cardiac and vascular group climbing about 6.2 percent to $2.81 billion. The company's diabetes business is smaller by sales, but grew quickly, with revenue reaching $572 million during the quarter. Sales were up about 26 percent from the first quarter of fiscal 2018, an increase that marked the unit's best performance as measured by quarterly revenue growth in more than 10 years, CEO and Chairman Omar Ishrak said in prepared remarks. Shares of Medtronic are up more than 5 percent on the news , to about $95. Sales of the companys MiniMed 670G device, which is its latest artificial pancreas system , partly drove the strong performance, the company said. The MiniMed 670G includes a sensor that monitors glucose levels in fluid under the skin. Based on data collected by the sensor, the device adjusts insulin delivery every five minutes. The companys market share in the diabetes-pump business rose 6 points during the quarter, Ishrak said. Sales of the companys Guardian Conn Continue reading >>

Urgent Recall - Medtronic Minimed Infusion Sets

Urgent Recall - Medtronic Minimed Infusion Sets

Medtronic, in consultation with the Therapeutic Goods Administrations (TGA), has issued a global recall of some infusion sets used with Medtronic insulin pumps. This recall was initiated following recent reports of the potential over-delivery of insulin shortly after an infusion set change. Over-delivery of insulin can cause hypoglycaemia. To determine if you have any recalled infusion sets go to The website will prompt you to enter the REF and LOT numbers for all of the infusion sets in your possession. You will then be told which of the infusion sets are included in the recall, and which are not. If you have any recalled infusion sets, please complete the online form. To ensure that your replacement request is processed, make sure you click the SUBMIT button once your form is complete. Once the online form is submitted, replacement box/es of infusion sets will be sent by Medtronic directly to your nominated delivery address, free of charge. Please cut-out and retain the barcodes on your recalled infusion set boxes. These should be placed in the reply-paid envelope that will be included in the delivery of the replacement infusion sets. Send this envelope back to Medtronic but do not return the recalled infusion sets. You can dispose of your recalled infusion sets once you have returned the barcode to Medtronic. The following link contains more information on the recall, including important safety information about avoiding potential insulin over-delivery: Please do not use any of the recalled infusion sets. If necessary, please make use of your diabetes self-management back-up plan as agreed with your health professional until Medtronic are able to replace your recalled products. Medtronic has advised that replacement infusion sets are made with new and enhanced materi Continue reading >>

More in diabetes